Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded at Zacks Research

Zacks Research upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a hold rating to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Other equities analysts have also recently issued reports about the company. HC Wainwright increased their price target on Vanda Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a report on Monday, January 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. B. Riley Financial raised their target price on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Finally, Wall Street Zen raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.63.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $6.09 on Wednesday. The firm’s 50-day moving average price is $7.35 and its 200-day moving average price is $5.68. Vanda Pharmaceuticals has a 52-week low of $3.81 and a 52-week high of $9.60. The company has a market cap of $359.92 million, a PE ratio of -1.63 and a beta of 0.62. The company has a quick ratio of 3.10, a current ratio of 2.39 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. The company had revenue of $57.22 million for the quarter, compared to the consensus estimate of $59.28 million. As a group, analysts anticipate that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Royal Bank of Canada raised its holdings in Vanda Pharmaceuticals by 34.3% during the first quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 14,232 shares during the period. Millennium Management LLC grew its position in shares of Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after purchasing an additional 1,470,898 shares in the last quarter. CWM LLC raised its stake in Vanda Pharmaceuticals by 424.6% during the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 7,575 shares during the period. R Squared Ltd bought a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $83,000. Finally, Los Angeles Capital Management LLC lifted its holdings in Vanda Pharmaceuticals by 17.8% in the 2nd quarter. Los Angeles Capital Management LLC now owns 44,696 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 6,765 shares in the last quarter. Institutional investors own 88.14% of the company’s stock.

More Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Zacks Research upgraded Vanda from a “hold” to a “strong‑buy,” which could attract buying interest from momentum and value‑oriented investors. Zacks/TickerReport Upgrade
• Neutral Sentiment: Company released its Q4 and full‑year 2025 financial results and an earnings call recap showing revenue growth but widening losses; this is the baseline data investors will parse for guidance and runway. Vanda Q4 & FY2025 Results (Press Release)
• Negative Sentiment: Q4 results missed expectations: EPS came in as a larger loss and revenue slightly trailed estimates, which prompted the stock reaction and investor uncertainty. Vanda: Q4 Earnings Snapshot
• Negative Sentiment: Vanda lowered FY‑2026 revenue guidance to roughly $230M–$260M versus a consensus near $273M, signaling slower near‑term growth and pressuring valuation and cash‑flow expectations. Guidance in Vanda Q4 Press Release
• Negative Sentiment: Regulatory uncertainty: analysts and commentary highlight meaningful FDA approval risk for Bysanti and imsidolimab, which raises binary event risk and could delay or reduce future revenues. TipRanks: Regulatory Hurdles for Bysanti and Imsidolimab
• Negative Sentiment: Investor legal risk: a Pomerantz LLP investigation into Vanda has been announced, which can increase near‑term sell pressure and legal costs if a suit proceeds. Pomerantz Investor Alert

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.